AstraZeneca commences CytoFab programme

The expanded phase of AstraZeneca’s CytoFab trials commenced yesterday with treatment of the first patient, it was reported by Protherics.

AstraZeneca’s study of the drug for the control of severe sepsis is expected to consist of two parts, with the second aimed at evaluating the safety and efficacy of CytoFab within a larger patient group.

Some 70 subjects will be involved in the study and the publication of a report is due in 12 months’ time.

Protherics is supplying CytoFab but AstraZeneca is responsible for development and commercialisation of the pharmaceutical product, following a licensing deal agreed at the end of 2005.

Severe sepsis is an inflammatory condition brought on by infection and causes a systemic response throughout the body. Although reactions vary, a fever and increased heart rate can lead to organ damage and death.

“AstraZeneca and Protherics have both undertaken a considerable programme of work since the signing of the licensing agreement,” remarked Dr John Rex, vice-president of clinical infection at AstraZeneca.

“We are delighted that the phase 2 programme with CytoFab is underway.”